Background: Lung cancer screening guidelines recommend using individualized risk models to refer ever-smokers for screening. However, different models select different screening populations. The performance of each model in selecting eversmokers for screening is unknown.
T
he NLST (National Lung Screening Trial) showed that 3 rounds of annual computed tomography (CT) screening reduced lung cancer deaths by 20% (1) . Annual CT screening for lung cancer is recommended by the U.S. Preventive Services Task Force (USPSTF) for smokers aged 55 to 80 years with at least 30 pack-years of smoking and no more than 15 years since smoking cessation (2) . However, there is growing recognition that, rather than selecting smokers for screening by using simple dichotomized risk factors, individualized risk calculators that account for certain demographic, clinical, and smoking characteristics could substantially enhance the effectiveness and efficiency of CT screening programs (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) . The most recent National Comprehensive Cancer Network guidelines for lung cancer screening (version 2.2018) permit use of risk models to refer ever-smokers for screening (14) .
Many lung cancer risk models have been proposed, but the performance of each in selecting eversmokers for screening remains unknown. Independent validation and critical comparison of the statistical properties of multiple risk models have been limited (15) (16) (17) . Of note, the comparative performance of risk models in selecting ever-smokers for screening in the U.S. population has not been evaluated. Critical evaluation and comparison are necessary to determine which models are appropriate for clinical use.
We applied 9 prominent lung cancer risk models to a representative sample of the U.S. population (the National Health Interview Survey [NHIS] from 2010 to 2012) and investigated the similarities and differences in the populations of ever-smokers selected for CT lung cancer screening by each model. We compared the number of ever-smokers chosen by each model at fixed risk thresholds and the extent of consensus among models on persons selected for screening, both overall and for subpopulations. In addition, we comprehensively evaluated and compared the statistical performance (calibration and discrimination) of the models in 
METHODS
We describe the process of identifying risk models and their characteristics, the 2 cohorts used to evaluate the external validity of model predictions, and the application of each model to NHIS data representative of the U.S. population to compare the implications of each model for the eligible screening population.
was not well-calibrated in NIH-AARP and CPS-II (Supplement Table 2 , available at Annals.org), we considered it to be superseded by the LCDRAT and excluded it, leaving 9 models for consideration. Details of each model are provided in the Supplement (available at Annals.org). Supplement Table 3 (available at Annals.org) compares the variables and their representations in the models. Most models included additional demographic and smoking-related risk factors beyond the USPSTF criteria. The LCRAT and the LCDRAT also used risk factors to better account for competing mortality.
Using publicly available risk calculators or software provided by model developers, we confirmed that all models were correctly replicated (Supplement Table 4 , available at Annals.org). We used our publicly available R package lcmodels (http://dceg.cancer.gov/tools/risk -assessment/lcmodels) to calculate risk from all 9 models.
Study Populations for External Model Validation
We used data from the NIH-AARP and CPS-II cohorts because they were not used in the development of any of the risk models and could therefore serve as external validation populations. The NIH-AARP cohort (described previously [25] ) enrolled 566 398 AARP members aged 50 to 71 years from 6 U.S. states and 2 metropolitan areas with high-quality cancer registries from 1995 to 1996. After exclusion of never-smokers and persons meeting other exclusion criteria (Supplement), 337 388 participants were included in our validation analysis. Incident lung cancer cases were identified via linkage to cancer registries. Because age at smoking initiation and years since quitting for former smokers are known only within specified intervals or are sometimes unknown, we created multiple-imputation data sets to impute these variables (Supplement).
The CPS-II Nutrition Survey cohort included 184 194 persons enrolled in 1992 and 1993 (26). After exclusion of never-smokers and persons meeting other exclusion criteria (Supplement), 72 338 participants were included in our validation analysis. Incident lung cancer cases were identified via self-report and were verified through released medical records or linkage with state cancer registries. Additional incident lung cancer cases were detected through linkage with the National Death Index and were verified when possible through linkage with state cancer registries.
Nationally Representative Study Population for Lung Cancer Screening Eligibility
The NHIS is a nationally representative survey that annually assesses the health of the civilian noninstitutionalized U.S. population (27). We previously constructed a contemporary U.S. screening population of 43 million ever-smokers aged 50 to 80 years in the 2010 to 2012 NHIS (13) . We imputed missing data on body mass index, race/ethnicity, education, years since quitting, and number of cigarettes smoked per day (Supplement).
In both study cohorts and the NHIS, cause of death was determined via linkage to the National Death Index.
Performance of Nine Lung Cancer Risk Prediction Models
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Statistical Analysis
External Validation of Risk Models
Model validity in NIH-AARP and CPS-II was assessed by calibration (the ratio and the difference in modelpredicted vs. observed cases [expected-observed]) and discrimination (receiver-operating characteristic curve and area under the curve [AUC]). In each cohort, we evaluated calibration overall and across demographic subgroups, by eligibility according to the USPSTF criteria, and across the risk range among persons who met the USPSTF criteria (Supplement). Discrimination was evaluated overall and by eligibility according to the USPSTF criteria for each model in each cohort. In addition, we investigated model performance for 3 scenarios: fixed specificity (the specificity achieved by the USPSTF criteria in each cohort), fixed sensitivity (the sensitivity achieved by the USPSTF criteria in each cohort), and fixed risk threshold (the threshold that would select the same number of persons as the USPSTF criteria in the U.S. population) (Supplement).
U.S. Population Eligible for Screening
Each model was applied to the 2010 to 2012 NHIS cohort to select 2 screening populations. First, each model selected a population based on a 5-year lung cancer risk threshold of 2.0% or a 5-year lung cancer death risk threshold of 1.2%; both of these thresholds are similar to the USPSTF criteria in the number of eversmokers selected (13) . We compared the sizes of these 9 populations. Because the models calculate risk across different time frames (1, 5, 6, 8.7 , and 10 years), we distributed 2.0% risk evenly over 5 years, resulting in approximately equivalent thresholds of 0.4% over 1 year, 2.4% over 6 years, 3.5% over 8.7 years, and 4.0% over 10 years. Second, each model picked the 8.9 million U.S. ever-smokers (the size of the population eligible for screening according to the USPSTF criteria in 2010 to 2012) with the highest model-estimated risk. We then calculated the number of persons who were chosen by all 9 models (consensus), or 8 out of 9, and so on.
All analyses were conducted in R, version 3.4.1 (28) . Analyses of NHIS data used the survey package (29) .
Role of the Funding Source
This study was supported by the Intramural Research Program of the NIH/National Cancer Institute. The NIH had no role in the design or conduct of the study; collection, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript. Table 1 compares characteristics of ever-smokers in the 4 research cohorts (NIH-AARP, CPS-II, PLCO, and NLST) and the nationally representative NHIS. In each of the research cohorts, minorities were underrepresented. The NIH-AARP and CPS-II cohorts had fewer current smokers (19.5% and 10.3%, respectively) than the U.S. population (34.2%), but smokers in these cohorts smoked at greater intensity and had more packyears of exposure. Figure 1 and Supplement Table 2 summarize the calibration of all models in NIH-AARP and CPS-II. Four models (the Bach model, PLCO M2012 , LCRAT, and LCDRAT) were well-calibrated in both cohorts (expectedobserved ratio range, 0.92 to 1.12). The Pittsburgh Predictor was well-calibrated in NIH-AARP (expectedobserved ratio, 1.01) but underestimated risk in CPS-II (expected-observed ratio, 0.83). The other 4 models (the Spitz and Hoggart models, LLP, and LLPi) overestimated risk, with expected-observed ratios ranging from 1.18 to 3.69 and expected-observed differences ranging from 55 to 857 cases per 100 000 persons per year. Overestimation was generally smaller for persons who met the USPSTF criteria (expected-observed ratio range, 0.96 to 2.51) than those who did not (expectedobserved ratio range, 1.64 to 5.76). However, among those meeting the USPSTF criteria, even the wellcalibrated models overestimated risk in the highest quintile (except for the Bach model in NIH-AARP) (Supplement Figure 1 , available at Annals.org).
RESULTS
Characteristics of Study Populations
Comparative Risk Model Performance in External Populations
For discrimination, the 4 well-calibrated models also had higher AUCs (range, 0.75 to 0.79) than the other 5 models (range, 0.62 to 0.75) ( Figure 1 and Supplement Table 2 ). Supplement Figure 2 (available at Annals.org) shows the receiver-operating characteristic curves for each model in each cohort. The USPSTF criteria achieved sensitivity and specificity of 0.67 and 0.67, respectively, in NIH-AARP and 0.48 and 0.81, respectively, in CPS-II. When specificity or sensitivity was fixed at the value for the USPSTF criteria in each cohort, performance (as measured by sensitivity and specificity) was best for LCDRAT but was generally similar across the 4 well-calibrated models (Supplement Tables 5 and 6, available at Annals.org). At a fixed risk threshold of 2.0% for lung cancer incidence or 1.2% for lung cancer death over 5 years, the 4 well-calibrated models performed similarly, with no model achieving both the highest sensitivity and the highest specificity in either NIH-AARP or CPS-II (Supplement Table 7 , available at Annals.org).
Comparative Risk Model Implications for U.S. Population Eligibility for Lung Cancer Screening
With a screening eligibility threshold of 2.0% lung cancer risk over 5 years, the 9 risk models chose populations ranging from 7.6 million to 26 million U.S. eversmokers ( Figure 2) . The well-calibrated models (the Bach model, PLCO M2012 , LCRAT, and LCDRAT) chose populations ranging from 7.6 million to 10.9 million. The Pittsburgh Predictor chose a population of 9.6 million. The other 4 models (the Spitz and Hoggart models, LLP, and LLPi) chose populations ranging from 14.5 million to 26 million. Of note, the USPSTF criteria selected 8.9 million ever-smokers for screening.
To account for possible miscalibration of the models, we compared the 8.9 million U.S. ever-smokers at ORIGINAL RESEARCH Performance of Nine Lung Cancer Risk Prediction Models Figure 3 , available at Annals.org). Only 20% (1.8 million) of ever-smokers were chosen by all 9 models and the USPSTF criteria. Of note, 17% of the ever-smokers selected by the USPSTF criteria were chosen by none of the models (1.5 million persons with an average 5-year risk for lung cancer incidence of 1.0% according to LCRAT and 5-year risk for lung cancer death of 0.6% according to LCDRAT). However, the 4 well-calibrated models (the Bach model, PLCO M2012 , LCRAT, and LCDRAT) achieved consensus on 73% (6.5 million) of ever-smokers (Supplement Figure 3) . In NIH-AARP, these values were imputed from the prevalence in the control group of PLCO. In NHIS, participants were asked whether they were told they had chronic bronchitis in the past year. ¶ In CPS-II, NLST, and NHIS, this was a continuous variable. In NIH-AARP and PLCO, participants selected a category. ** In CPS-II, PLCO, NLST, and NHIS, this was a continuous variable. The models also differed in the numbers of ever-smokers chosen in other subgroups based on age, smoking status (current vs. former), family history of lung cancer, or presence of chronic obstructive pulmonary disease (COPD) (emphysema or bronchitis) (Supplement Tables 8 and 9 , available at Annals.org).
Performance of Risk Models in Racial/Ethnic and Other Subgroups
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DISCUSSION
To inform future guidelines for risk-based selection of ever-smokers for CT lung cancer screening, we compared the U.S. screening populations selected by 9 risk models and evaluated model predictions in 2 large U.S. cohorts. The models differed widely in the number of ever-smokers they selected (7.6 million to 26 million), and there was no consensus on which ever-smokers to select for screening. These disagreements were due to the different predictive performance of the models. Four models (the Bach model, PLCO M2012 , LCRAT, and LCDRAT) performed best, as measured by calibration and discrimination. These models picked similar numbers of ever-smokers for screening (7.6 million to 10.9 million) and showed the best agreement on which ever-smokers to select.
We found that the 4 best-performing models (the Bach model, PLCO M2012 , LCRAT, and LCDRAT) had the highest discrimination overall, the highest sensitivity at a fixed specificity and vice versa, and similar discrimination at a fixed risk threshold. These observations indicate that any of these models could be used to select U.S. smokers who are at the greatest risk for lung cancer incidence or death. Each of these models has been validated in external cohorts (13, 16, 17, 30 ) and has a readily available online risk calculator. Of note, the 
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LCDRAT was previously validated in the NHIS, which is a representative sample of the U.S. population (13) .
This study is the first to compare model-selected populations for CT lung cancer screening. The populations differed by nearly 20 million ever-smokers because the largest ones were picked by models that overestimated risk by factors of 2 to 3 (LLPi and the Hoggart and Spitz models). The lack of consensus in selection of ever-smokers at the highest risk is due to different risk factor effects between models. Although the models do not select identical ever-smokers at the highest risk because they incorporate different risk factors, 17% of those chosen by the USPSTF criteria were chosen by none of the models. These findings show that available risk models have different implications for whom to offer screening and underscore the importance of thorough evaluation of model performance in populations being considered for screening. Validation in nationally representative samples or populations is particularly important because research cohorts often recruit volunteers who are healthier than the general population (31) . For example, a validation study of LCDRAT in the NHIS revealed a hitherto unreported healthy volunteer effect in the NLST, where lung cancer mortality rates were 24% lower than expected (13) .
This study represents the most comprehensive external validation of available lung cancer risk models in the U.S. population, both overall and across key subgroups. Previous efforts focused on single models (30) or did not validate in cohorts (15) , except for a study that compared 4 models (the Bach and Spitz models, LLP, and PLCO M2012 ) in a cohort of Germans (16) . Of note, a recent study compared the statistical performance of 3 of the models we evaluated (the Bach model, LLP, and PLCO M2012 ) in the NLST and the PLCO (17) and concluded that they were well-calibrated on the basis of visual examination (17) .
Our results highlight the need to improve calibration in important subpopulations, even in the 4 wellcalibrated models, which overestimated risk in the heaviest smokers and chose different numbers of current smokers. The Bach model and the Pittsburgh Predictor do not account for race/ethnicity, family history of lung cancer, or presence of COPD and chose either too few or too many persons compared with models that account for those variables. PLCO M2012 underestimated risk in Hispanics by a factor of 2 to 3 and chose the fewest Hispanics. The LCRAT and the LCDRAT underestimated risk in the "Asian/other" subgroup and chose the fewest in this subgroup. Thus, even the bestperforming models require refinements to improve prediction in certain subpopulations.
The models that overestimated risk (LLP, LLPi, and the Hoggart and Spitz models) used case-control data or were based on European data. Potential problems with case-control data include recall bias of smoking histories and lack of population representativeness of cases and controls. Europe differs from the United States in many aspects of tobacco consumption, such as cigarette composition, antitobacco policies, and cultural smoking habits (32) . Understandably, European models do not use data on U.S. racial/ethnic minorities. Lung cancer risk may be generally higher in Europe than the United States, even for persons with given smoking histories (33) . Therefore, models based on U.S. data may poorly predict risk in Europe, although this was not observed in the German study (16) .
The Pittsburgh Predictor, which uses only 4 risk factors, outperformed several of the other models, but not the best-calibrated ones. Because the Pittsburgh Predictor does not account for years since quitting in former smokers, race/ethnicity, family history of lung cancer, or presence of COPD, it may not perform well in those subpopulations. The model requires a calculator and thus should be no easier to use clinically than other models, provided that unknown risk factors are suitably imputed in the other models.
Our study has limitations. The 2 research cohorts used for validation (NIH-AARP and CPS-II) are not representative of the U.S. population and underrepresent racial/ethnic minorities. Also, both cohorts recruited participants during the 1990s and thus are not representative of smoking exposure in the contemporary Our chosen 5-y risk thresholds for lung cancer (2.0%) and lung cancer death (1.2%) yielded numbers close to the number selected with the USPSTF criteria (8.9 million). Lung cancer risk of 2.0% over 5 y is equivalent to approximately 0.4% of the population developing lung cancer each year. Approximately equivalent risk thresholds for models that do not provide 5-y risks are 4.0% after 10 y for the Bach model, 0.4% after 1 y for the Spitz and Hoggart models, 3.5% after 8.7 y for LLPi, and 2.4% after 6 y for PLCO M2012 and the Pittsburgh Predictor. The risk thresholds needed to select 8.9 million ever-smokers are 4.8% after 10 y for the Bach model, 1.2% after 1 y for the Spitz model, 3.5% after 5 y for LLP, 8.1% after 8.7 y for LLPi, 1.3% after 1 y for the Hoggart model, 2.0% after 6 y for PLCO M2012 , 2.9% after 6 y for the Pittsburgh Predictor, 2.0% after 5 y for LCRAT, and 1. 
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Performance of Nine Lung Cancer Risk Prediction Models U.S. population. In addition, given the lack of consensus on a risk threshold for selection of U.S. smokers for screening, we used illustrative examples that would select the same number of ever-smokers as the USPSTF criteria.
Few eligible ever-smokers currently undergo lung cancer screening, in part because of lack of knowledge about screening among providers and the general population and limited access to screening for Medicaid beneficiaries or uninsured persons (34) . Furthermore, research is needed to develop and evaluate shared decision-making tools and processes for riskbased lung cancer screening. The University of Michigan lung cancer screening tool, which uses PLCO M2012 and the Bach model, has been in use for more than 2 years (35) . PLCO M2012 is downloadable (https://brocku .ca/lung-cancer-risk-calculator). Another tool, the Lung Cancer Screening Decision Tool (36), uses the Bach lung cancer death model (24), which we could not validate because we could not obtain its parameters. We have developed an online lung cancer screening risk tool, the Risk-based NLST Outcomes Tool (https: //analysistools.nci.nih.gov/lungCancerScreening), that presents individual risk for not only lung cancer (using LCRAT) but also lung cancer death (using LCDRAT) and false-positive CT screening results (13) . Our R package lcrisks (https://dceg.cancer.gov/tools/risk-assessment /lcrisks) calculates risks from LCRAT and LCDRAT, and our R package lcmodels (https://dceg.cancer.gov/tools /risk-assessment/lcmodels) calculates risks from all 9 models. A Web site is also available to calculate risks using LCRAT and LCDRAT (https://analysistools.nci.nih .gov/lungCancerRiskAssessment).
To revise screening guidelines to allow risk-based selection for lung cancer screening, consensus must be reached on a cost-effective risk threshold for screening eligibility. One proposal, a 6-year risk of 1.51% (11), was based not on cost-effectiveness but on a visually noted decrease in prevented lung cancer deaths in the NLST as a function of risk (9) . Our example of 5-year risk of 2.0% selects similar numbers of smokers as the USPSTF criteria (13) , but this also is not based on cost-effectiveness. Risk thresholds could be based on lung cancer incidence or mortality, which resulted in similar screening populations.
Ending the epidemic of smoking-related illness requires continued progress in smoking cessation and prevention. Effectively and efficiently targeting lung cancer screening to persons at highest risk can further reduce lung cancer mortality, the leading type of cancer death. Our findings suggest that 4 lung cancer risk 
